2.50
Hdl Handle:
http://hdl.handle.net/10541/108133
Title:
A phase I and pharmacokinetic study of amphethinile.
Authors:
Smith, David B; Ewen, C; Mackintosh, J; Fox, Brian W; Thatcher, Nick; Scarffe, J Howard; Vezin, R; Crowther, Derek
Abstract:
Amphethinile is a new spindle poison with a novel structure that has shown activity in the L1210, ADJ/PC6 and Walker carcinoma rodent tumours. In addition the agent appeared to have an improved therapeutic ratio compared to existing spindle poisons and is well absorbed when administered orally. The starting dose for the phase I study was 40 mg m-2 (1/10th mouse LD10) and further patients were studied at 200, 400, 800 and 1200 mg m-2, dose escalation being based on pharmacological monitoring. Significant toxic effects were seen only at 800 and 1200 mg m-2. At these doses patients experienced nausea and vomiting, light headedness during the infusion and varying degrees of lethargy following therapy. Two of six patients at 800 mg m-2 developed severe pain in the tumour bearing area 1-2 h after treatment and one experienced colicky abdominal pain. At 1200 mg m-2 two patients died within 48 h of treatment from what appeared to be vascular causes. Following these episodes the trial was discontinued. Neutropenia and alopecia occurred in two patients, one at 800 and one at 1200 mg m-2. These patients achieved the highest drug exposure in terms of area under the concentration x time curve. It was not possible to achieve an AUC consistently high enough to produce cytotoxic effects due to the occurrence of dose limiting toxicities thus amphethinile cannot at present be recommended for phase II testing by the i.v. route. The dose escalation scheme based on pharmacological monitoring resulted in a considerable saving in the duration of the trial. Further evaluation of this methodology is recommended.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, Manchester, UK.
Citation:
A phase I and pharmacokinetic study of amphethinile. 1988, 57 (6):623-7 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Jun-1988
URI:
http://hdl.handle.net/10541/108133
PubMed ID:
3408647
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorSmith, David Ben
dc.contributor.authorEwen, Cen
dc.contributor.authorMackintosh, Jen
dc.contributor.authorFox, Brian Wen
dc.contributor.authorThatcher, Nicken
dc.contributor.authorScarffe, J Howarden
dc.contributor.authorVezin, Ren
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-07-22T08:21:53Z-
dc.date.available2010-07-22T08:21:53Z-
dc.date.issued1988-06-
dc.identifier.citationA phase I and pharmacokinetic study of amphethinile. 1988, 57 (6):623-7 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid3408647-
dc.identifier.urihttp://hdl.handle.net/10541/108133-
dc.description.abstractAmphethinile is a new spindle poison with a novel structure that has shown activity in the L1210, ADJ/PC6 and Walker carcinoma rodent tumours. In addition the agent appeared to have an improved therapeutic ratio compared to existing spindle poisons and is well absorbed when administered orally. The starting dose for the phase I study was 40 mg m-2 (1/10th mouse LD10) and further patients were studied at 200, 400, 800 and 1200 mg m-2, dose escalation being based on pharmacological monitoring. Significant toxic effects were seen only at 800 and 1200 mg m-2. At these doses patients experienced nausea and vomiting, light headedness during the infusion and varying degrees of lethargy following therapy. Two of six patients at 800 mg m-2 developed severe pain in the tumour bearing area 1-2 h after treatment and one experienced colicky abdominal pain. At 1200 mg m-2 two patients died within 48 h of treatment from what appeared to be vascular causes. Following these episodes the trial was discontinued. Neutropenia and alopecia occurred in two patients, one at 800 and one at 1200 mg m-2. These patients achieved the highest drug exposure in terms of area under the concentration x time curve. It was not possible to achieve an AUC consistently high enough to produce cytotoxic effects due to the occurrence of dose limiting toxicities thus amphethinile cannot at present be recommended for phase II testing by the i.v. route. The dose escalation scheme based on pharmacological monitoring resulted in a considerable saving in the duration of the trial. Further evaluation of this methodology is recommended.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAnimals-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshDrug Evaluation-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshIndoles-
dc.subject.meshMale-
dc.subject.meshMice-
dc.subject.meshMice, Inbred Strains-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasms-
dc.titleA phase I and pharmacokinetic study of amphethinile.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.